The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies
Open accessAbstract
BACKGROUND: Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. METHODS: Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. FINDINGS: During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1·43, 95% CI 1·31-1·56; p<0·0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1·37 (95% CI 1·29-1·46; p<0·0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0·0001), being definitely increased only for the two most common types, serous (RR 1·53, 95% CI 1·40-1·66; p<0·0001) and endometrioid (1·42, 1·20-1·67; p<0·0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1·25, 95% CI 1·07-1·46, p=0·005). INTERPRETATION: The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users. FUNDING: Medical Research Council, Cancer Research UK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,805
(2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70425-4 · Cited by 1,160
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Ovarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) · The Lancet · doi:10.1016/s0140-6736(08)60167-1 · Cited by 822
Self-citationEstrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
Rodriguez, C. (2001) · JAMA · doi:10.1001/jama.285.11.1460 · Cited by 424
de Villiers, T. J., Pines, A., Panay, N., Gambacciani, M., Archer, D. F., Baber, R. J., Davis, S. R., Gompel, A. A., Henderson, V. W., Langer, R., et al. (2013) · Climacteric · doi:10.3109/13697137.2013.795683 · Cited by 298
Improved estimates of floating absolute risk
Plummer, M. (2004) · Statistics in Medicine · doi:10.1002/sim.1485 · Cited by 265
(2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70322-4 · Cited by 249
Cited by
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Global cancer in women: burden and trends.
Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M., & Jemal, A. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0858 · Cited by 1,245
Metadata
- Authors
- Collaborative Group on Epidemiological Studies of Ovarian Cancer
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 385
- Issue
- 9980
- Pages
- 1835-1842
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1695897458
- Cited by
- 472
- References
- 12
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. https://app.cochat.ai/papers/10.1016/s0140-6736(14)61687-1
- The paper
- Collaborative Group on Epidemiological Studies of Ovarian Cancer. (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. The Lancet. https://doi.org/10.1016/s0140-6736(14)61687-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.